Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$164.31
pos +1.30
+0.77%
Today's Range: 163.21 - 164.80 | AMGN Avg Daily Volume: 4,129,500
Last Update: 03/30/17 - 3:59 PM EDT
Volume: 2,261,298
YTD Performance: 11.52%
Open: $164.07
Previous Close: $163.06
52 Week Range: $130.09 - $181.81
Oustanding Shares: 736,452,791
Market Cap: 121,301,139,206
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 5 4
Moderate Buy 1 1 1 1
Hold 9 9 10 11
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.16 2.16 2.28 2.41
Latest Dividend: 1.15
Latest Dividend Yield: 2.79%
Dividend Ex-Date: 05/15/17
Price Earnings Ratio: 16.08
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
16.08 16.10 30.50
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
10.34% 9.08% 35.26%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.10 0.20 0.07
Net Income 11.30 0.50 0.15
EPS 13.00 0.50 0.15
Earnings for AMGN:
EBITDA 12.03B
Revenue 22.99B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $2.98 $3.10 $12.26 $12.72
Number of Analysts 10 8 13 11
High Estimate $3.11 $3.36 $12.94 $13.66
Low Estimate $2.80 $2.91 $11.80 $12.29
Prior Year $2.90 $2.84 $11.65 $12.26
Growth Rate (Year over Year) 2.59% 9.07% 5.23% 3.74%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Get your plan in place, but understand that the Republic is not in jeopardy.
Update
Mar 21, 2017 | 7:15 AM EDT
Thomson ONE Oppenheimer Healthcare Conference (Day 1 of 2) - 03/21/17 - 03/22/17 New York, NY
These stocks are showing signs of changing direction.
Today's session is reminiscent of a pre-Trump day.
This reversal has been incredible to watch.

Health Care Putting in a Base Real Money Pro($)

Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (XLV) (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. Last year more than $18 billion was redeemed out of the healthcare ETFs, according to Morningstar. However there are some technical signposts that the two-year period of underperformance might be ending, as a basing seems likely. Look at the chart and note the recent higher high.
Why the name is sagging, and what it will take to spur the sector higher.
Drug companies are the latest targets/beneficiaries.

Columnist Conversations

The DJIA has been making lows at a fairly regular interval of 101 days. The cycle tools overlaid on the daily ...
this stock continues to move well, momentum is strong. BOUGHT JACK MAY 100 CALL AT 5.25
I have a special guest joining me today, legendary technician Marc Chaikin comes aboard tonight, talking about...
View Chart »  View in New Window » To fail or not to fail is the question.  The video I d...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.